Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Luzu: 1% (60 g) [contains benzyl alcohol, methylparaben, propylene glycol]
Generic: 1% (60 g)
Mechanism of Action
Azole antifungal that appears to inhibit ergosterol synthesis by inhibiting the enzyme lanosterol demethylase, resulting in decreased amounts of ergosterol and a corresponding accumulation of lanosterol.
Small amounts may be absorbed following topical application
>99%; to plasma proteins
Use: Labeled Indications
Fungal infections: Topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum and Epidermophyton floccosum
There are no contraindications listed in the manufacturer's labeling.
Dosage and Administration
Fungal infections: Topical:
Tinea pedis: Apply to affected area and ~1 inch of immediate surrounding area(s) once daily for 2 weeks
Tinea cruris or tinea corporis: Apply to affected area and ~1 inch of immediate surrounding area(s) once daily for 1 week
Refer to adult dosing.
Fungal infections: Topical:
Tinea pedis or tinea cruris: Children ≥12 years and Adolescents: Refer to adult dosing
Tinea corporis: Children ≥2 years and Adolescents: Refer to adult dosing
For topical use only. Not for ophthalmic, oral, or intravaginal use. Apply to affected area and ~1 inch of immediate surrounding area(s). Wash hands following application.
Store at 20°C to 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F).
There are no known significant interactions.
<1%, postmarketing, and/or case reports: Application site reaction, cellulitis, contact dermatitis
- Appropriate use: For topical use only; not for oral, ophthalmic, or intravaginal use.
Adverse events were observed in some animal reproduction studies. Small amounts of luliconazole are absorbed systemically.
- Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
- Have patient report immediately to prescriber severe skin irritation (HCAHPS).
- Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.